# China NMPA Drug Inspection - Chongqing Baoyuantang Pharmaceutical Co., Ltd. - Ginseng

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/chongqing-baoyuantang-pharmaceutical-co-ltd/c90ee304-1cd3-4da6-a5a3-48a2fbb37dd1/
Source feed: China

> China NMPA drug inspection for Chongqing Baoyuantang Pharmaceutical Co., Ltd. published December 28, 2017. Drug: Ginseng. The Chongqing Municipal Food and Drug Administration (CMFDA) issued its 2017 Issue No. 7 Drug Quality Announcement on De

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Chongqing Municipal Food and Drug Administration's Drug Quality Bulletin, Issue No. 7, 2017
- Company Name: Chongqing Baoyuantang Pharmaceutical Co., Ltd.
- Publication Date: 2017-12-28
- Drug Name: Ginseng
- Inspection Finding: Inspection did not meet regulations
- Action Taken: Control measures such as sealing, seizing, suspending sales, and recalling products have been taken, and the production company is being investigated and dealt with in accordance with relevant laws and regulations.
- Summary: The Chongqing Municipal Food and Drug Administration (CMFDA) issued its 2017 Issue No. 7 Drug Quality Announcement on December 27, 2017, following inspections conducted by three regional testing institutes. These inspections identified nine batches of substandard drugs from several manufacturers. Key companies implicated include Chongqing Kangwanjia Traditional Chinese Medicine Pieces Co., Ltd., Children's Hospital Affiliated to Chongqing Medical University, Chongqing Yuhetang Pharmaceutical Co., Ltd., Chongqing Changhang Hospital, and Chongqing Wanyuanjia Pharmaceutical Co., Ltd., which had multiple product issues. The main violations related to drug quality and specifications, specifically involving appearance, moisture content, product properties, and active ingredient content, indicating a failure to meet required standards. Under the CMFDA's regulatory framework, district and county branches were mandated to take immediate control measures. These actions included sealing, seizing, suspending sales, and recalling the identified substandard drugs. Additionally, the implicated manufacturers are required to investigate the root causes of these deficiencies, formulate and implement comprehensive rectification measures, and eliminate potential future risks. Investigations and enforcement actions are ongoing in accordance with relevant laws and regulations.

Company: https://www.globalkeysolutions.net/companies/chongqing-baoyuantang-pharmaceutical-co-ltd/4d8d1d54-9127-4897-8c2e-318f36b8a500/